Авитотамиг
AvitotamigМНН
Rec. INN (наименование, зарегистрированное ВОЗ)
USAN (наименование, принятое к употреблению в США)
CAS
2577961-36-3
Химическое название
immunoglobulin G1_L-kappa-scFvhk, anti-[Homo sapiens CD33 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3, gp67, p67)] and anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)], humanized monoclonal antibody, bipecific, tetravalent;H-gamma1 heavy chain anti-CD33 humanized (1-449) [VH (Homo sapiens IGHV1-2*02 (85.7%) -(IGHD) -IGHJ4*01 (86.7%) T122>S (113), L123>S (114), CDR-IMGT [8.8.12] (26-33.51-58.97-108)) (1-119) -Homo sapiens IGHG1*01v, G1m17,1>G1m3,1 CH1 R120, CH3 D12, L14, G1v29 CH2 A84.4, G1v20 CH2 A105 (CH1 R120 (216) (120-217), hinge 1-15 (218-232), CH2 N84.4>A (299), K105>A (324) (233-342), CH3 D12 (358), L14 (360) (343-447), CHS (448-449)) (120-449)], (222-213')-disulfide with the L-kappa-scFvhk chain humanized (1'-486') [L-kappa light chain anti-CD33 humanized (1'-213') [V-KAPPA (Homo sapiens IGKV1-33*01 (88.3%) -IGKJ2*01 (88.3%) Q120>A (99'), I126>L (105') , CDR-IMGT [6.3.8] (27'-32'.50'-52'.89'-96')) (1'-106') -Homo sapiens IGKC*01 (100%), Km3, A45.1 (152'), V101 (190') (107'-213')] -17-mer threonyl-seryl-tris(tetraglycyl-seryl) linker (214'-230') -scFvhk anti-CD3E humanized (231'-486') [VH (Homo sapiens IGHV3-30*10 (70.4%) -(IGHD) -IGHJ4*01 (85.7%) L123>P (344'), CDR-IMGT [8.8.12] (255'-263'.281'-288'.327'-338') C114>S (335')) (231'-349') -30-mer hexakis(tetraglycyl-seryl) linker (350'-379') -V-KAPPA (Homo sapiens IGKV1-33*01 (81.1%) -(IGHD) -IGKJ2*02 (80.0%) Q120>C (478'), E125>Q (483'), CDR-IMGT [5.3.9] (406'-410'.428'-430'.467'-475')) (380'-486')]]; dimer (228-228'':231-231'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-DG44, non-glycosylated
Структура
Иностранные названия
- Avitotamigum (латинское)
- Avitotamig (английское)
- Avitotamig (немецкое)
- Avitotamig (французское)
- Avitotamig (испанское)
Подробнее по теме
Узнайте дополнительные сведения о действующем веществе Авитотамиг: